NCT02059278View on ClinicalTrials.gov

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

335

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Primary Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

T-2345

T-2345 Ophthalmic Solution

DRUG

Xalatan

Xalatan (latanoprost 0.005% ophthalmic solution)

Trial Locations (1)

Unknown

El Paso

Sponsors
All Listed Sponsors
lead

Nephron Pharmaceuticals Corporation

INDUSTRY